CARE-AF: Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation

What this Trial Is About

Researchers are studying patients with atrial fibrillation (AF), a common heart rhythm disorder, to better understand why some still experience ischemic strokes despite taking oral anticoagulant therapy (OAC). The study focuses on identifying clinical factors, cardiac serum biomarkers, and heart structure features that may be linked to breakthrough strokes and could improve risk prediction in high-risk AF patients. This observational study is conducted at a single center and aims to include at least 500 participants. Participants with AF who have had an acute ischemic stroke will be enrolled, including those with breakthrough strokes despite OAC use. The study does not involve any intervention but collects detailed clinical data, blood samples for cardiac biomarkers, and echocardiographic measurements of the left atrium and its appendage. Patients will undergo standardized follow-up visits every 12 months after enrollment, with a minimum follow-up period of 12 months. During the study, researchers will assess recurrent ischemic stroke or systemic embolism as the primary outcome, measured at the first follow-up around 12 months and annually thereafter. Secondary outcomes include all-cause death, major adverse cardiac events, episodes of symptomatic AF, and functional outcomes such as disability and quality of life. The study aims to enhance understanding of stroke risk factors in AF patients to guide future treatment decisions and improve risk stratification.

Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation